Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best pricing metric to use for them?
Other featured articles
Newly Approved Cancer Drugs Are Pricey, But Also Show Improved Longer-Term Survival Gains, According to New Study
Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
Who Would Have Believed it? Markets Can Reduce the ‘True’ Price of Cancer Drugs
When it comes to cancer, however, it is the price of health — not the price of drugs — that matters. As we think about ways to wring value out of the health care system, we acknowledge that CMS reforms and markets seem to be working in therapeutic areas with rapid innovation.
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
About this section
Chronic diseases are among the most preventable and costliest conditions, consuming the overwhelming majority of Medicare resources. The Schaeffer Center assembles leading minds from across disciplines to address this challenge, striving to simplify labyrinthine systems of care and promote healthier outcomes.